Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells

被引:74
作者
Gu, Xuesong
Zerbini, Luiz F.
Otu, Hasan H.
Bhasin, Manoj
Yang, Quanli
Joseph, Marie G.
Grall, Franck
Onatunde, Tomi
Correa, Ricardo G.
Libermann, Towia A.
机构
[1] Beth Israel Deaconess Med Ctr, BIDMC Genom Ctr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Med Polymer Ctr, Natl Inst Family Planning, Beijing, Peoples R China
[4] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA
关键词
D O I
10.1158/0008-5472.CAN-06-3689
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The epithelium-specific Ets transcription factor, PDEF, plays a role in prostate and breast cancer, although its precise function has not been established. In prostate cancer, PDEF is involved in regulating prostate-specific antigen expression via interaction with the androgen receptor and NKX3.1, and down-regulation of PDEF by antiproliferative agents has been associated with reduced PDEF expression. We now report that reduced expression of PDEF leads to a morphologic change, increased migration and invasiveness in prostate cancer cells, reminiscent of transforming growth factor beta (TGF beta) function and epithelial-to-mesenchymal transition. Indeed, inhibition of PDEF expression triggers a transcriptional program of genes involved in the TGF beta pathway, migration, invasion, adhesion, and epithelial dedifferentiation. Our results establish PDEF as a critical regulator of genes involved in cell motility, invasion, and adhesion of prostate cancer cells.
引用
收藏
页码:4219 / 4226
页数:8
相关论文
共 42 条
[1]   Comparative analysis of algorithms for signal quantitation from oligonucleotide microarrays [J].
Barash, Y ;
Dehan, E ;
Krupsky, M ;
Franklin, W ;
Geraci, M ;
Friedman, N ;
Kaminski, N .
BIOINFORMATICS, 2004, 20 (06) :839-846
[2]   TGF-β/Smad signaling in prostate cancer [J].
Bello-DeOcampo, D ;
Tindall, DJ .
CURRENT DRUG TARGETS, 2003, 4 (03) :197-207
[3]   ETV6: A versatile player in leukemogenesis [J].
Bohlander, SK .
SEMINARS IN CANCER BIOLOGY, 2005, 15 (03) :162-174
[4]   E-cadherin and β-catenin are down-regulated in prostatic bone metastases [J].
Bryden, AAG ;
Hoyland, JA ;
Freemont, AJ ;
Clarke, NW ;
Wismayer, DS ;
George, NJR .
BJU INTERNATIONAL, 2002, 89 (04) :400-403
[5]  
Chen H, 2002, CANCER RES, V62, P338
[6]   Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach [J].
de Pinieux, G ;
Legrier, ME ;
Poirson-Bichat, F ;
Courty, Y ;
Bras-Gonçalves, R ;
Dutrillaux, AM ;
Némati, F ;
Oudard, S ;
Lidereau, R ;
Broqua, P ;
Junien, JL ;
Dutrillaux, B ;
Poupon, MF .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) :753-764
[7]   DAVID: Database for annotation, visualization, and integrated discovery [J].
Dennis, G ;
Sherman, BT ;
Hosack, DA ;
Yang, J ;
Gao, W ;
Lane, HC ;
Lempicki, RA .
GENOME BIOLOGY, 2003, 4 (09)
[8]   Molecular markers for predicting prostate cancer stage and survival [J].
Dunsmuir, WD ;
Gillett, CE ;
Meyer, LC ;
Young, MP ;
Corbishley, C ;
Eeles, RA ;
Kirby, RS .
BJU INTERNATIONAL, 2000, 86 (07) :869-878
[9]  
Ellenrieder V, 2001, CANCER RES, V61, P4222
[10]  
EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739